Stomach cancer is the fifth largest cancer in the world. Despite many combinations of
studies, metastatic stomach cancer shows a median survival period of 10 to 12 months.
According to a report in Korea in 2010, 17 % of cancer patients had over-expression of human
epidemiology growth factor receptor 2 (HER-2). And Using of Trastuzumab reported better
results.Herzuma® is the Trastuzumab biosimilar (Biosimilar) cloned antibody.
In this study, the investigators want to prospectively analyze the effects and side effects
of Herzuma® in gastric or gastroesophageal adenocarcinoma.